Da Hee Han, PharmD

Most Recent Articles by Da Hee Han, PharmD

First Generic Version of Sabril Tablets Gets FDA Approval

First Generic Version of Sabril Tablets Gets FDA Approval

By

As treatment with vigabatrin may be associated with permanent vision loss, the generic tablets are also part of a single shared-system Risk Evaluation and Mitigation Strategy (REMS) program to ensure the product is used safely.

FDA Approves Two New Strengths of Apadaz for Pain Management

FDA Approves Two New Strengths of Apadaz for Pain Management

By

Apadaz was initially approved in February 2018 as 6.12mg/325mg immediate-release tablets for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

Bafiertam Gets Tentative Approval for Relapsing Multiple Sclerosis

Bafiertam Gets Tentative Approval for Relapsing Multiple Sclerosis

By

Bafiertam is a new fumarate bioequialent alternative to its prodrug, Tecfidera (dimethyl fumarate; Biogen).

FDA to Review Treatment for Jet Lag Disorder

FDA to Review Treatment for Jet Lag Disorder

By

In the Phase 3 JET8 study (N=318), patients underwent a circadian challenge of 8 hours in advance to their usual bedtime.

Parkinson Disease Treatment Soon to Be Discontinued

Parkinson Disease Treatment Soon to Be Discontinued

By

Requip and Requip XL are non-ergot dopamine agonists indicated for the treatment of Parkinson disease.

More Articles by Da Hee Han, PharmD

Sign Up for Free e-newsletters



CME Focus